Rosemary Steinmetz
Indiana University
23 Papers
126 Citations
Rosemary Steinmetz is an academic researcher from Indiana University. The author has contributed to research in topics: Signal transduction & Estrogen. The author has an hindex of 14, co-authored 23 publications. Previous affiliations of Rosemary Steinmetz include University of Cincinnati Academic Health Center.
Chat about Author
Papers
Extrapituitary Prolactin: Distribution, Regulation, Functions, and Clinical Aspects*
TL;DR: This review addresses the concept of the dual function of PRL, as a circulating hormone and a cytokine, based on its shared properties with hematopoietic growth factors.
739
The environmental estrogen bisphenol A stimulates prolactin release in vitro and in vivo
TL;DR: BPA mimics estradiol in inducing hyperprolactinemia in genetically predisposed rats and the in vivo action is mediated, at least in part, by increasing PRL regulating factor activity in the posterior pituitary.
499
Differential expression of GRK isoforms in nonmalignant and malignant human granulosa cells
Denise Walker King,Rosemary Steinmetz,Heather A. Wagoner,Tamara S. Hannon,Lin Yuan Chen,Erica A. Eugster,Ora H. Pescovitz +6 more
TL;DR: Findings suggest that GRK protein expression is altered in GCTs and may be involved in the pathogenesis of these tumors.
49
Is McCune-Albright syndrome overlooked in subjects with fibrous dysplasia of bone?
Tamara S. Hannon,Ken Noonan,Rosemary Steinmetz,Erica A. Eugster,Michael A. Levine,Ora H. Pescovitz +5 more
TL;DR: A substantial proportion of children being followed for fibrous dysplasia of bone have unrecognized clinical and laboratory features of McCune-Albright syndrome and are at risk for endocrinopathy and should be screened accordingly.
44
RNA interference (RNAi) for extracellular signal-regulated kinase 1 (ERK1) alone is sufficient to suppress cell viability in ovarian cancer cells
TL;DR: Treatment of ovarian cancer cells with small inhibitory RNAs directed against ERK1 and ERK2 leads to the induction of apoptosis and necrosis by four hours following treatment, and it is found that primary, non-malignant ovarian cells do not respond similarly to ERK siRNA treatment and that these cells fail to die following treatment.
42